Phase 2 N=10 RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia
Male Infertility, Azoospermia
Primary: Total Motile Sperm — 8; 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=171 Males, Antioxidants, and Infertility Trial
Male Infertility
Primary: Live Birth Rate — 15.3; 22.1 percentage of live births
N/A N=108 A Sibling Oocyte Study- Comparison of ZyMotTM Microfluidics Device to Density Gradient for Sperm Selection During ICSI
ART
Primary: Percentage of Good Quality Blastocyst Formation — 51.4; 51.7 percentage of embryos
N/A N=241 Prednisolone Improves IVF Outcomes in Men With Anti-sperm Antibodies
Reproductive Sterility
Primary: Number of Control and Treated Participants With Successful Live Births Following Conventional IVF or ICSI Cycles — 18; 13; 8; 9 participants
N/A N=114 Impact of DNA Fragmentation in Sperm on Pregnancy Outcome After Intra-uterine Insemination in a Spontaneous Cycle
Infertility Unexplained · Infertility, Male · DNA Damage
Primary: DNA Fragmentation as a Predictor of Live Birth Rate — 32 Participants — p=0.04
N/A N=386 Sperm Selection by Microfluidic Separation Improves Embryo Quality
Sperm DNA Fragmentation · Embryo Quality · Fertility Disorders
Primary: Day 3 High Quality Embryo Percentage — 68; 66 percentage of high quality embryos
N/A N=10 HOP-2A - Intratesticular Hormone Levels
Healthy · Male Infertility · Prostate Disease
Primary: Intratesticular Hormones in Normal Men — 486; 3.0; 3.7; 0.20 ng/mL
Phase 2 N=20 RA-2 13-cis Retinoic Acid (Isotretinoin)
Male Infertility · Klinefelter's Syndrome · Y-chromosome Microdeletions
Primary: Millions of Sperm Per Ejaculate — 2.5; 3.8 Millions of sperm per ejaculate
N/A N=80 Assessment of TetraSOD® Efficacy to Improve Semen Parameters in Men With Idiopathic Infertility
Infertility, Male
Primary: Sperm Progressive Motility — 19.62; 25.11 percentage
Phase 2 N=40 ITT4 Intratesticular Hormonal Milieu in Man (ITT4)
Healthy Males
Primary: Intratesticular Testosterone (IT-T) Level — 14; 3.7; 1.7; 18.4 ng/mL — p=<0.05
Phase 2 N=17 To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
Secondary Hypogonadism
Primary: Sperm Concentration — 0.54; 72.8; 3.00; 182.6 millions sperm/mL — p=0.118
N/A N=2,370 Folic Acid and Zinc Supplementation Trial (FAZST)
Pregnancy · Live Birth · Spontaneous Abortion
Primary: Live Birth — 404; 416; 97; 91 Participants
Phase 3 N=181 Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism
Secondary Hypogonadism
Primary: Subjects With Testosterone in Normal Range After Treatment — 81.3 Percentage of Subjects
Phase 3 N=151 Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism
Secondary Hypogonadism
Primary: Proportion (Percentage) of Androxal Treated Subjects With Testosterone in the Normal Range — 78.8 Percentage of Subjects
Phase 2 N=40 HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
Healthy Males
Primary: Serum Testosterone (T) — 0.43; 1.5; 3.7; 8.4 nmol/liter — p=<0.05
Phase 4 N=60 Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
Hypogonadism, Male
Primary: Change in Testosterone Levels From Baseline to 27 Weeks — 652 ng/dL
Phase 2 N=20 Atrasentan Spermatogenesis and Testicular Function
Nephropathy · Diabetes
Primary: Percentage of Subjects With a Sperm Concentration < 15 Million Per mL by Treatment Week 26 — 23.5 percentage of participants
N/A N=739 Impact of Sperm DNA Integrity on In Vitro Cycles
Male Infertility · Unexplained Infertility · Abortion, Habitual
Primary: Pregnancy — 67; 80 participants
Phase 2 N=33 The Effect and Safety of Lisinopril in Non-hypertensive Men With Infertility From Low Sperm Count
Oligospermia
Primary: Changes From Baseline in the Seminal Fluid Characteristics Throughout the Study — 3.47; 3.20 ml
N/A N=570 Assessing the Rates of Major Complications in Combined Mini-incision Microscopic Varicocelectomy
Varicocele
Primary: Recurrent Varicocele — 2; 16 participants
Phase 2 N=110 Ultrasound Guided Aspiration of Hydrosalpingeal Fluid and IVF-ET Outcomes
Infertility
Primary: The Number of Participants Who Achieved Clinical Pregnancy in a Transfer Cycle — 17; 7 participents — p=0.023
N/A N=24 Plan A Novel Delivery Device Study
Healthy Male Adults Participants · Vasectomy
Primary: Adverse Events — 10 Participants
N/A N=28 Investigating the Physiological Effects of Weight Loss on Male Fertility
Male Infertility · Obesity · Weight Loss
Primary: Sperm Concentration — 53.6; 58.5; 20.1; 15 million sperms/mL
Phase 4 N=181 Study Evaluating the Effects of Avanafil on Semen Parameters
Erectile Dysfunction
Primary: Percentage of Subjects With a Greater Than or Equal to 50% Decrease in Sperm Concentration From Baseline to Week 26 — 1.5; 14.5 percentage of participants
Phase 3 N=18 A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)
Hypogonadism · Hypogonadotropic Hypogonadism
Primary: Change From Baseline in Log-Transformed Testicular Volume at Week 52 — 2.3 Fold change
Phase 3 N=499 Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism
Secondary Hypogonadism
Primary: Change From Baseline in Total Morning Testosterone at 26 Weeks — 280.9; 214.7 ng/dL
Phase 4 N=59 A Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valganciclovir (Valcyte®) Versus Untreated Matched Controls
Cytomegalovirus Infections
Primary: Change in Sperm Density From Baseline to the End of Treatment (EOT) — -9.770; 30.396 mil/mL — p=0.0075
Phase 4 N=50 Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine
Male Infertility
Primary: Pain Scores 48 Hours After Surgery — 118.4; 98.2 Scores*Hour — p=0.41
N/A N=52 Fertility Preservation in Male AYA With Cancer
Infertility, Male
Primary: Fertility Preservation (FP) Uptake — 10; 9 Participants — p==.64
N/A N=29 Investigational Oocyte Cryopreservation for Medical and Non Medical Indications
Infertility, Female · Deferred Childbearing
Primary: Fertility Quality of Life Questionnaire Completed After One Year After Oocyte Cryopreservation for Non-medical Reasons — 9 Participants